ASCO conference reports from the Citeline team: updates from Allogene Therapeutics Inc., AstraZeneca PLC, Daiichi Sankyo Co., Ltd., Servier, Merck & Co., Inc., Bicara Therapeutics , Roche Holding AG, Elevation Oncology, Inc., and ImmunoGen, Inc.
Allogene has taken a step closer to developing a viable off-the-shelf CAR-T therapy, becoming the first to match the durability...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?